Assignee
SELECTA BIOSCIENCES INC
US·20 granted patents·55 pending applications·333 citations·filing 2010–2023
Top patents by PatentIndex Score
75 records- 0197US11298342B2Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivitySELECTA BIOSCIENCES INC·Filed 2019·Granted Apr 12, 2022·7 cites·20 claims
- 0297US10668053B2Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigenSELECTA BIOSCIENCES INC·Filed 2014·Granted Jun 2, 2020·13 cites·16 claims
- 0397US10046064B2Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Aug 14, 2018·21 cites·13 claims
- 0497US9993548B2Tolerogenic synthetic nanocarriers for inducing regulatory B cellsSELECTA BIOSCIENCES INC·Filed 2014·Granted Jun 12, 2018·30 cites·17 claims
- 0596US10441651B2Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cellsSELECTA BIOSCIENCES INC·Filed 2015·Granted Oct 15, 2019·16 cites·15 claims
- 0696US10420835B2Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cellsSELECTA BIOSCIENCES INC·Filed 2015·Granted Sep 24, 2019·17 cites·19 claims
- 0796US10071114B2Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Sep 11, 2018·20 cites·14 claims
- 0896US10039822B2Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Aug 7, 2018·31 cites·24 claims
- 0996US9764031B2Dose selection of adjuvanted synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2015·Granted Sep 19, 2017·35 cites·18 claims
- 1095US11235057B2Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2018·Granted Feb 1, 2022·8 cites·17 claims
- 1195US10434088B2Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective doseSELECTA BIOSCIENCES INC·Filed 2014·Granted Oct 8, 2019·15 cites·22 claims
- 1295US10357483B2Methods comprising dosing combinations for reducing undesired humoral immune responsesSELECTA BIOSCIENCES INC·Filed 2014·Granted Jul 23, 2019·14 cites·20 claims
- 1395US10357482B2Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivitySELECTA BIOSCIENCES INC·Filed 2014·Granted Jul 23, 2019·16 cites·20 claims
- 1495US10335395B2Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2014·Granted Jul 2, 2019·14 cites·20 claims
- 1595US9884112B2Immunomodulatory agent-polymeric compoundsSELECTA BIOSCIENCES INC·Filed 2015·Granted Feb 6, 2018·22 cites·36 claims
- 1695US9006254B2Immunomodulatory agent-polymeric compoundsSELECTA BIOSCIENCES INC·Filed 2013·Granted Apr 14, 2015·33 cites·27 claims
- 1794US11633422B2Methods and compositions for attenuating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2015·Granted Apr 25, 2023·6 cites·12 claims
- 1894US11426451B2Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressantSELECTA BIOSCIENCES INC·Filed 2018·Granted Aug 30, 2022·7 cites·12 claims
- 1993US11779641B2Tolerogenic synthetic nanocarriers for allergy therapySELECTA BIOSCIENCES INC·Filed 2016·Granted Oct 10, 2023·3 cites·18 claims
- 2092US11717569B2Tolerogenic synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2016·Granted Aug 8, 2023·5 cites·19 claims
- 2190US2024350462A1Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2290US2024261396A1Tolerogenic synthetic nanocarriers for allergy therapySELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2388US2023321225A1Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteinsSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2487US2023321224A1Tolerogenic synthetic nanocarriers to reduce antibody responsesSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2587US2023310593A1Tolerogenic synthetic nanocarriers for allergy therapySELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2686US2024156955A1Tolerogenic synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2785US2023364124A1Methods and compositions for attenuating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2881US2020101155A1Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cellsSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 2981US2020101154A1Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cellsSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3079US2020113874A1Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective doseSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3179US2022354947A1Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesSELECTA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3279US2022071968A1Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3377US2023107561A1Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressantSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3473US2020069660A1Methods comprising dosing combinations for reducing undesired humoral immune responsesSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3573US2020069659A1Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune toleranceSELECTA BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3670US2020390881A1Nanocarriers possessing components with different rates of releaseSELECTA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3767US2023139671A1Osmotic mediated release synthetic nanocarriersSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3866US2024148841A1Compositions and methods related to immunoglobulin proteases and fusions thereofSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3966US2024024517A1Viral vector dosing protocolsSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4065US2023372535A1Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agentsSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4164US2018256709A1Immunomodulatory agent-polymeric compoundsSELECTA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4264US2023263906A1High affinity il-2 receptor agonists and synthetic nanocarrier dose sparingSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4364US2019076458A1Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responsesSELECTA BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4463US2023322884A1Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosingSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4563US2023140196A1Viral vector dosing protocolsSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4663US2023357437A1Immunosuppressants in combination with anti-igm agents and related dosingSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4763US2014242173A1Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agentsSELECTA BIOSCIENCES INC·Filed 2014·Application pending·0 cites
- 4863US2023381277A1High affinity il-2 receptor agonists and immunosuppressants to enhance immune toleranceSELECTA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4962US2014030344A1Targeted synthetic nanocarriers with ph sensitive release of immunostimulatory agentsSELECTA BIOSCIENCES INC·Filed 2013·Application pending·0 cites
- 5061US2023141563A1Methods and compositions for attenuating anti-viral transfer vector igm responsesSELECTA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SELECTA BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →